SCHEMBL26985106

SCHEMBL26985106

Cc1c(CO)cncc1Nc1ccccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCL8 P10145 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ NPC1 O15118 4/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ RAD52 P43351 1/20 0.37
▸ PIM1 P11309 2/20 0.37
▸ PIM2 Q9P1W9 2/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ BAD Q92934 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ MAPT P10636 3/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ USP2 O75604 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ RECQL P46063 1/20 0.36
▸ MITF O75030 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30746586 1.00 CXCL8 (0.43) CXCL8KDM4ENPC1RAB9ARAD52
SCHEMBL26985139 0.81 NUDT1 (0.47) NPC1RAB9AMAPTKMT2AALDH1A1
SCHEMBL30746508 0.81 TP53 (0.40) NPC1RAB9AMAPTL3MBTL1
SCHEMBL30746528 0.81 NUDT1 (0.47) NPC1RAB9AMAPTKMT2AALDH1A1
SCHEMBL26984972 0.81 TP53 (0.40) NPC1RAB9AMAPTL3MBTL1
SCHEMBL26985120 0.73 KDM4E (0.45) CXCL8KDM4ENPC1RAB9APIM1
SCHEMBL31613387 0.73 KDM4E (0.45) CXCL8KDM4ENPC1RAB9APIM1
SCHEMBL20121220 0.71 PDXK (0.37) KDM4EKMT2AALDH1A1HSD17B10LMNA
SCHEMBL29793294 0.69 CXCL8 (0.55) CXCL8KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL396120 0.69 CXCL8 (0.55) CXCL8KDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
EP-4551558-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS Nested Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 CXCL8 4128/4885KDM4E 2144/4885NPC1 2276/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 CXCL8 2441/4885KDM4E 1608/4885NPC1 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback